In this episode, host Nicola Hill explores the hypothesis that fully virtualised decentralized clinical trials (DCT), that operate invisibly, will make traditional models obsolete within the next decade.
Joining her are Craig Lipset, Co-Chair of the Decentralized Trials and Research Alliance, and Lewis Millen, UCB’s Global Clinical Science and Operations Innovation Lead. Together, they unpack the plausibility, benefits and challenges of this shift, from inclusivity and patient convenience to technological hurdles and regulatory readiness. Is a hybrid model the future, or will decentralized clinical trials render old paradigms irrelevant?
This podcast is produced and funded by UCB.
Hosted on Acast. See acast.com/privacy for more information.
","author_name":"UCB Biopharma "}